iTRAQ-based proteomics reveals novel biomarkers of osteoarthritis.
iTRAQ-based proteomics reveals novel biomarkers of osteoarthritis.
复制标题
DOI：
10.3109/1354750x.2013.810667
复制
发表时间：
2013-11
期刊：
影响因子：
--
通讯作者：
Yamada H
中科院分区：
文献类型：
--
作者：
Ikeda D;Ageta H;Tsuchida K;Yamada H
我们使用相对和绝对定量的同量异位素标签（iTRAQ）方法对关节软骨进行了全面的蛋白质组学分析，并寻找骨关节炎（OA）的候选生物标志物。 对照组为OA或股骨颈骨折患者的关节软骨。通过iTRAQ方法检测分子变异，并通过western blot进行定量分析。 使用iTRAQ方法，我们鉴定了OA患者和对照组中具有不同表达水平的76种蛋白质。在这些蛋白质中，我们选择了LECT 2（白细胞来源的趋化因子-2），BAALC（脑和急性白血病，细胞质），和PRDX 6（过氧化物氧还蛋白-6），这还没有被报道为OA的生物标志物。 这些蛋白与传统OA生物标志物联合使用可能更好地反映OA的分级和预后。
We performed comprehensive proteomic analyses of articular cartilage by using the isobaric tags for relative and absolute quantitation (iTRAQ) method, and searched for candidate biomarkers for osteoarthritis (OA). Articular cartilage was collected from patients with OA or femoral neck fracture for the control group. Molecular variations were detected by the iTRAQ method, and quantitative analyses were performed by western blot. Using the iTRAQ method, we identified 76 proteins with different expression levels in OA patients and the control group. Among these proteins, we selected LECT2 (leukocyte cell-derived chemotaxin-2), BAALC (brain and acute leukemia, cytoplasmic), and PRDX6 (peroxiredoxin-6), which had not been reported as biomarkers for OA. Use of these proteins in combination with conventional OA biomarkers may better reflect the grade and prognosis of OA.